Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 724-732

  Bailey, Melanie L ^a   O'Neil, Nigel J ^a   Van Pel, Derek M ^b   Solomon, David A ^c   Waldman, Todd ^d   Hieter, Philip ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centre for Drug Research and Development   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; RUCAPARIB; TEMOZOLOMIDE; VELIPARIB;

ALLELE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE G2 PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENE; GENE MUTATION; GENOMIC INSTABILITY; GLIOBLASTOMA; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MICRONUCLEUS; NONSENSE MUTATION; PRIORITY JOURNAL; STAG 2 GENE; TARGET CELL;

ANTIGENS, NUCLEAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA REPAIR; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; MUTATION; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84896309068     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0749     Document Type: Article

References (49)

1. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
3. Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, et al. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010;70:5389-98.
4. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15. (Pubitemid 44299177)
5. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, Peralta A, Valenzuela MT, Matinez-Romero R, et al. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol 2007;8:29.
6. Wang X, Weaver DT. The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res 2011;1:301-27.
7. Dorsett D, Strom L. The ancient and evolving roles of cohesin in gene expression and DNA repair. Curr Biol 2012;22:R240-50.
8. Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. Annu Rev Genet 2009;43:525-58.
9. O'Neil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends Genet 2013;29:290-7.
10. Wu N, Yu H. The smc complexes in DNA damage response. Cell Biosci 2012;2:5.
11. Caron P, Aymard F, Iacovoni JS, Briois S, Canitrot Y, Bugler B, et al. Cohesin protects genes against gammaH2AX induced by DNA double-strand breaks. PLoS Genet 2012;8:e1002460.
12. Strom L, Lindroos HB, Shirahige K, Sjogren C. Postreplicative recruitment of cohesin to double-strand breaks is required for DNA repair. Mol Cell 2004;16:1003-15. (Pubitemid 40018409)
13. Tittel-Elmer M, Lengronne A, Davidson MB, Bacal J, Francois P, Hohl M, et al. Cohesin association to replication sites depends on rad50 and promotes fork restart. Mol Cell 2012;48:98-108.
14. McLellan JL, O'Neil NJ, Barrett I, Ferree E, van Pel DM, Ushey K, et al. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 2012;8:e1002574.
15. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011;333:1039-43.
16. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37. (Pubitemid 46795129)
17. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007;6:945-56. (Pubitemid 46554564)
18. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012;30:283-8.
19. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997;75:337-49. (Pubitemid 127733184)
20. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-85. (Pubitemid 23267698)
21. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
22. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10.
23. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150:264-78.
24. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45:1232-7.
25. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-74.
26. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013;45:1428-30.
27. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013;45:1464-9.
28. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459-63.
29. Sjogren C, Nasmyth K. Sister chromatid cohesion is required for postreplicative double-strand break repair in saccharomyces cerevisiae. Curr Biol 2001;11:991-5. (Pubitemid 32589193)
30. Bauerschmidt C, Arrichiello C, Burdak-Rothkamm S, Woodcock M, Hill MA, Stevens DL, et al. Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin. Nucleic Acids Res 2010;38:477-87.
31. Rudra S, Skibbens RV. Cohesin codes - interpreting chromatin architecture and the many facets of cohesin function. J Cell Sci 2013;126:31-41.
32. Luo H, Li Y, Mu JJ, Zhang J, Tonaka T, Hamamori Y, et al. Regulation of intra-S phase checkpoint by ionizing radiation (IR)-dependent and IR-independent phosphorylation of SMC3. J Biol Chem 2008;283:19176-83.
33. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev 2004;18:1423-38. (Pubitemid 38780629)
34. Bauerschmidt C, Woodcock M, Stevens DL, Hill MA, Rothkamm K, Helleday T. Cohesin phosphorylation and mobility of SMC1 at ionizing radiation-induced DNA double-strand breaks in human cells. Exp Cell Res 2011;317:330-7.
35. Hauf S, Roitinger E, Koch B, Dittrich CM, Mechtler K, Peters JM. Dissociation of cohesin from chromosome arms and loss of arm cohesion during early mitosis depends on phosphorylation of SA2. PLoS Biol 2005;3:e69.
36. Chou DM, Adamson B, Dephoure NE, Tan X, Nottke AC, Hurov KE, et al. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A 2010;107:18475-80.
37. Gagne JP, Pic E, Isabelle M, Krietsch J, Ethier C, Paquet E, et al. Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress. Nucleic Acids Res 2012;40:7788-805.
38. Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, et al. APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. EMBO J 2012;31:1160-76.
39. Yadav S, Sehrawat A, Eroglu Z, Somlo G, Hickey R, Yadav S, et al. Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PLoS ONE 2013;8:e64338.
40. Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90.
41. Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JC, Kirkby KJ, et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 2013;8:65.
42. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013;71:1191-9.
43. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011;71:5626-34.
44. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009;15:7277-90.
45. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 2008;6:1621-9.
46. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 2011;39:3607-20.
47. Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, et al. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 2009;7:1686-92.
48. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly (ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010;9:1775-87.
49. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2-new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE 2011;6:e27183.